[Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy].
Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease. The time until partial response in the first case was 7 months and in the second case 12 months. Adverse events were slight, though a standard dose as a single drug was used for each drug. The treatment time course was shortened because capecitabine was an oral drug. Therefore, this combination therapy was expected to maintain high quality of life and obtain a high response rate.
Inoue
Shingo
S
First Dept. of Surgery, Faculty of Medicine, University of Yamanashi.
Inoue
Masayuki
M
Takahashi
Hifumi
H
Inoue
Ayako
A
Kunitomo
Kazuyoshi
K
Fujii
Hideki
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D014057:Tomography, X-Ray Computed; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D000069287:Capecitabine; D000068878:Trastuzumab; D005472:Fluorouracil